New treatment options for fibromyalgia: Critical appraisal of duloxetine

Neuropsychiatric Disease and Treatment

Volumn 4, Issue 3, 2008, Pages 525-529

  Üçeyler, Nurcan ^a   Offenbächer, Martin ^b   Petzke, Frank ^c   Häuser, Winfried ^d   Sommer, Claudia ^a,e  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d Center of Pain Therapy   (Germany)

^e NONE   (Germany)

Author keywords

Antidepressant; Duloxetine; Fibromyalgia syndrome; Review; SNRI

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; DULOXETINE; FLUOXETINE; MILNACIPRAN; NORADRENALIN UPTAKE INHIBITOR; PARACETAMOL; PLACEBO; PREGABALIN; SEROTONIN UPTAKE INHIBITOR;

ANALGESIC ACTIVITY; ANOREXIA; APPETITE; ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; DIABETIC NEUROPATHY; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FIBROMYALGIA; HEART RATE; HUMAN; INSOMNIA; LOW DRUG DOSE; MAJOR DEPRESSION; NAUSEA; NERVOUSNESS; PAIN; PAIN ASSESSMENT; PHYSICAL DISABILITY; QUALITY OF LIFE; RHINOPHARYNGITIS; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SWEATING; XEROSTOMIA;

EID: 47849086290     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Arnold LM, Crofford LJ, Martin SA, et al. 2007. The effect of anxiety and depression on improvements in pain in a randomized, controlled trial of pregabalin for treatment of fibromyalgia. Pain Med, 8:633-8.
2. Arnold LM, Lu Y, Crofford LJ, et al. 2004. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum, 50:2974-84.
3. Arnold LM, Rosen A, Pritchett YL, et al. 2005. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain, 119:5-15.
4. Bennett RM, Jones J, Turk DC, et al. 2007. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord, 8:27.
5. Boonen A, van den Heuvel R, van Tubergen A, et al. 2005. Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitis. Ann Rheum Dis, 64:396-402.
6. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. 2001. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology, 25:871-80.
7. Carville SF, Arendt-Nielsen S, Bliddal H, et al. 2008. EULAR evidence based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis, 67:536-41.
8. Crofford U, Rowbotham MC, Mease PJ, et al. 2005. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum, 52:1264-73.
9. Detke MJ, Lu Y, Goldstein DJ, et al. 2002. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry, 63:308-15.
10. Goldenberg D, Smith N. 2003. Fibromyalgia, rheumatologists, and the medical literature: a shaky alliance. J Rheumatol, 30:151-3.
11. Goldenberg DL, Burckhardt C, Crofford L. 2004. Management of fibromyalgia syndrome. Jama, 292:2388-95.
12. Goldstein DJ, Lu Y, Detke MJ, et al. 2004. Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics, 45:17-28.
13. Goldstein DJ, Lu Y, Detke MJ, et al. 2005. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain, 116:109-18.
14. Goldstein DJ, Mallinckrodt C, Lu Y, et al. 2002. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry, 63:225-31.
15. Gran JT. 2003. The epidemiology of chronic generalized musculoskeletal pain. Best Pract Res Clin Rheumatol, 17:547-61.
16. Henriksson CM, Liedberg GM, Gerdle B. 2005. Women with fibromyalgia: work and rehabilitation. Disabil Rehabil, 27:685-94.
17. Jadad AR, Moore RA, Carroll D, et al. 1996. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 17:1-12.
18. Millan MJ. 2002. Descending control of pain. Prog Neurobiol, 66:355-474.
19. Penrod JR, Bernatsky S, Adam V, et al. 2004. Health services costs and their determinants in women with fibromyalgia. J Rheumatol, 31:1391-8.
20. Raskin J, Pritchett YL, Wang F, et al. 2005. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med, 6:346-56.
21. Robinson RL, Jones ML. 2006. In search of pharmacoeconomic evaluations for fibromyalgia treatments: a review. Expert Opin Pharmacother, 7:1027-39.
22. van Koulil S, Effting M, Kraaimaat FW, et al. 2007. Cognitive-behavioural therapies and exercise programmes for patients with fibromyalgia: state of the art and future directions. Ann Rheum Dis, 66:571-81.
23. Vitton O, Gendreau M, Gendreau J, et al. 2004. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol, 19(Suppl 1):S27-35.
24. White KP, Speechley M, Harth M, et al. 1999. The London Fibromyalgia Epidemiology Study: direct health care costs of fibromyalgia syndrome in London, Canada. J Rheumatol, 26:885-9.
25. Wolfe F, Ross K, Anderson J, et al. 1995. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum, 38:19-28.
26. Wolfe F, Smythe HA, Yunus MB, et al. 1990. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum, 33:160-72.